Почетна › Рак на црн дроб (хепатоцелуларен карцином) › Илиноис
Клинички испитувања за Рак на црн дроб (хепатоцелуларен карцином) во Илиноис
20 студии за Рак на црн дроб (хепатоцелуларен карцином) бараат учесници на локации во Илиноис.
Градови во Илиноис
Официјален текст на студијата (англиски)
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #26, Chicago
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 1.10.2026 · NCT05176483Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
- Memorial Hospital, Shiloh
- Siteman Cancer Center - Shiloh, Shiloh
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 28.9.2026 · NCT07227012National Liver Cancer Screening Trial
- Northwestern University, Chicago
Се регрутираФаза 4
Возраст од 18 до 85 · Сите полови · Ажурирано 25.9.2026 · NCT06084234A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
- Local Institution - 0107, Chicago
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 23.9.2026 · NCT07291076Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure
- OSF St. Francis Medical Center, Peoria
Се регрутираФаза 2
Возраст од 18 до 100 · Сите полови · Ажурирано 23.9.2026 · NCT07219459A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- City of Hope Chicago Cancer Center, Zion
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 16.9.2026 · NCT06427941Defining the Ablative Dose for Y-90 TARE
- Northwestern University, Chicago
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 15.9.2026 · NCT07586046Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)
- RUSH University Medical Center, Chicago
- University of Chicago, Chicago
Се регрутираНабљудувачка студија
Возраст 22 и постари · Сите полови · Ажурирано 11.9.2026 · NCT06486454Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
- Research Site, Chicago
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 3.9.2026 · NCT06921785Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Lurie Children's Hospital-Chicago, Chicago
Се регрутираФаза 1/2
12 Months – 30 Years · Сите полови · Ажурирано 25.8.2026 · NCT04851119Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
- Carle at The Riverfront, Danville
- и уште 6
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 17.8.2026 · NCT07166406A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Orchard Healthcare Research Inc, Skokie
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 5.8.2026 · NCT06330064Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer
- University of Chicago Comprehensive Cancer Center, Chicago
- Carle Cancer Center NCI Community Oncology Research Program, Urbana
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 4.8.2026 · NCT05168163DRAGON Registry - International Multicenter Registry and Medical Image Bank for Patients With Primarily Unresectable Liver Cancer or Liver Metastases That Underwent Combined Portal and Hepatic Vein Embolization (PVE/HVE) to Increase Future Liver Remnant Before Resection.
- Rush University Medical Center, Chicago
Се регрутираНабљудувачка студија
Возраст 18 и постари · Сите полови · Ажурирано 21.7.2026 · NCT07717437Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Liver Cancer
- Northwestern University, Chicago
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 25.6.2026 · NCT07042919A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
- Clinical Trial Site, Chicago
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 17.6.2026 · NCT06600321Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk
- Northwestern University, Chicago
- Northwestern Medicine Kishwaukee Hospital, DeKalb
- Northwestern Medicine Delnor Hospital, Geneva
- и уште 4
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 26.5.2026 · NCT05620771Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
- University of Chicago Medical Center, Chicago
- Methodist Medical Center of Illinois, Peoria
Се регрутираФаза 4
Возраст од 18 до 64 · Сите полови · Ажурирано 22.1.2026 · NCT04373564SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Chicago
Се регрутираНабљудувачка студија
Сите возрасти · Сите полови · Ажурирано 28.10.2025 · NCT03452774The Dragon PLC Trial (DRAGON-PLC)
- Rush University Medical Center, Chicago
Се регрутира
Возраст 18 и постари · Сите полови · Ажурирано 15.5.2025 · NCT06914648Од ClinicalTrials.gov, податоци преземени 6.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.